Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for three months ended March 31, 2026.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for three months ended March 31, 2026
- Exhibit 99.1 contains the underlying earnings release and detailed financial metrics
- Results furnished under Regulation FD, limiting Exchange Act Section 18 liability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.